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Ubiquitinandubiquitin-relatedproteinsposttranslationallymodifysubstrates,andtherebyalter thefunctions oftheirtargets.The
ubiquitination process is involved in various physiological responses, and dysregulation of components of theubiquitin system has
been linked to many diseases including skin cancer. The ubiquitin pathways activated among skin cancers are highly diverse and
may reﬂect the various characteristics of the cancer type. Basal cell carcinoma and squamous cell carcinoma, the most common
types of human skin cancer, are instances where the involvement of the deubiquitination enzyme CYLD has been recently high-
lighted. In basal cell carcinoma, the tumor suppressor protein CYLD is repressed at the transcriptional levels through hedgehog
signaling pathway. Downregulation of CYLD in basal cell carcinoma was also shown to interfere with TrkC expression and
signaling,therebypromotingcancerprogression.Bycontrast,thelevelofCYLDisunchangedinsquamouscellcarcinoma,instead,
catalyticinactivationofCYLDintheskinhasbeenlinkedtothedevelopmentofsquamouscellcarcinoma.Thispaperwillfocuson
the current knowledge that links CYLD to nonmelanoma skin cancers and will explore recent insights regarding CYLD regulation
of NF-κB and hedgehog signaling during the development and progression of these types of human tumors.
1. The Ubiquitin System
The posttranslational modiﬁcation of diﬀerent proteins
via direct, covalent ubiquitin attachment regulates stability,
function, and localization of the modiﬁed protein. Ubiquitin
is covalently bound to ε-amino groups of lysine (K) residues
or, less commonly, to amino termini of substrate proteins.
Substrates can be modiﬁed, either by a monoubiquitin, or
a polyubiquitin chain(s) (polyubiquitination). Monoubiqui-
tination is involved in at least three distinct cellular func-
tions: histone regulation, endocytosis, and the budding of
retroviruses from the plasma membrane. Diﬀerent forms of
polyubiquitinareknowntotargetproteinsfordiﬀerentcellu-
lar fates. For example, K48-, K29-, and K11-linked polyubiq-
uitin chains target substrates for proteasome-mediated deg-
radation. K63-linked polyubiquitin chains appear to func-
tionindependentlyofproteasomaltargetingandinsteadtrig-
ger diverse cellular processes, including DNA repair, receptor
traﬃcking, and endocytosis or modulate the activity of kin-
ases and transcription factors, thereby enable cells to inter-
pret signals from their environment [1, 2]( Figure 1). Ubiq-
uitin modiﬁcation is reversed by the action of enzymes
known as deubiquitinating enzymes (DUBs) [3]s u c ha sc y l -
indromatosis gene (CYLD). DUBs generally cleave mono- or
polyubiquitin chains with substrate speciﬁcity, and, as has
beenestablished,DUBscandistinguishbetweenthediﬀerent
types of linkages in the polyubiquitin chains. In this regard,
CYLD was shown to only disassemble K63-linked polyu-
biquitin chains from diﬀerent substrates. Recent molecular
investigation has provided us with a better understanding of
how the tumor suppressor gene CYLD can regulate a variety
of signaling pathways that are linked to tumor cell prolifer-
ation and survival by cleavage of the ubiquitin chains from
target proteins. This paper will focus on the role of CYLD in
the nonmelanoma skin cancers, basal cell carcinoma (BCC),
and squamous cell carcinoma (SCC).2 Journal of Skin Cancer
Figure 1: Ubiquitin conjugation pathway. The ubiquitin pathway relies on a cascade of three enzymes, named ubiquitin-activating enzyme
(E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-ligating enzyme (E3), which conjugate ubiquitin to target proteins. First, ubiquitin
is activated by the E1 enzyme in an ATP-dependent manner. As a consequence, ubiquitin is covalently bound to E1 via thioester bond with
cysteine residue in the active site of the E1 enzyme. The ubiquitin is transferred to the active cysteine in E2 enzyme. Finally, with the help
of an E3 enzyme, ubiquitin is conjugated to its target substrate where diﬀerent ubiquitin-ubiquitin linkages help to decide the fate of the
modiﬁed protein. Ubiquitination is primarily associated with degradation of the tagged protein by the 26S proteasome (Lys-48), but it has
also nondegradative functions (Lys-63) such as the regulation of DNA repair and endocytosis amongst other functions. Enzymes known as
deubiquitinating enzymes (DUBs) can remove ubiquitin from proteins.
2. CYLDand Cylindromatosis
CYLD was originally discovered in families with multiple
cylindromas, a rare benign skin disease. Linkage analysis
mapped the susceptibility CYLD gene to a single locus on
chromosome 16q in aﬀected families, where both germline
and somatic mutations occurred [4]. This discovery suggest-
ed that loss of heterozygosity (LOH) of this novel tumor
suppressor gene due to mutations is associated with the de-
velopment of inherited familial cylindromatosis [5].
Brooke-Spiegler syndrome (BSS, OMIM 605041), famil-
ialcylindromatosis(FC,OMIM132700),andmultiplefamil-
ial trichoepithelioma (MFT, OMIM 601606) were originally
described as separate diseases that display certain clinical
similarities.PatientswithBSSarepredisposedtotheprogres-
sive development of cylindromas, trichoepitheliomas, and
spiradenomas,whereasFCischaracterizedbymultiplecylin-
dromas and MFT by trichoepithelioma as the only tumor
type. The inherited occurrence of cylindromas and tri-
choepitheliomas was also found to be combined within a
single genetic defect [6, 7]. CYLD function, however, is not
limited to its role in the etiology of cylindromas and tri-
choepitheliomas but has also been shown to act as a tumor
suppressor in multiple types of human cancers such as mel-
anoma, colon, lung, and multiple myeloma (for paper, see
[8]).
Human and mouse CYLD genes are very closely related
and highly conserved (95% homology). The CYLD gene
product is ubiquitously expressed in humans and mice. In
the skin, speciﬁcally in hair follicles, CYLD levels were found
to be elevated in the catagen phase of the hair cycle when
cell proliferation ceases [9]. CYLD protein contains three
cytoskeletal-associated protein-glycine-conserved (CAPGly)
domains and one zinc-ﬁnger-like B-box motif within the
ubiquitin carboxy-terminal hydrolases domain (UCH or
USP; Ub-speciﬁc proteases). The CAP-Gly domains of
CYLD are important for CYLD relocalization or binding to
substrates and function as scaﬀolding [10], whereas the USP
domainhydrolyzesubiquitinchains[11].Invitroandinvivo
analyses have previously indicated that a single mutation in
the Cys601 (CYLDC/S) located in the USP domain abolishes
the deubiquitin activity of CYLD [12–14].
Recently, a number of speciﬁc substrates for CYLD were
identiﬁed from which CYLD could remove the ubiqui-
tin chains by direct association. Furthermore, insights intoJournal of Skin Cancer 3
the normal functions and signaling interactions of the CYLD
gene product indicate that CYLD interferes with NF-κB-,
JNK-,WNT-,andp38MAPKsignalingtolimitinﬂammation
and cancer depending upon the tissue-/cell-type or in vivo
modelsystem[10].TRAF-2andTRAF-6weretheﬁrstspecif-
ic CYLD substrates identiﬁed from which CYLD was shown
to remove K63- linked polyubiquitin chains while also atten-
uating TNF-α-induced classical NF-κB signaling [12–14].
3. Regulation of Signaling by Ubiquitination
3.1. NF-κB Signaling. N u c l e a rf a c t o rk a p p aB( N F - κB) is
the generic name for a family of dimers formed by several
proteins: NF-κB1 (also known as p50/p105), NF-κB2 (also
known as p52/p100), c-Rel, RelA (also known as p65), and
RelB. The diﬀerent NF-κB heterodimers recognize a com-
mon consensus DNA sequence and regulate a large number
of target genes, especially those involved in the immune sys-
tem and also genes involved in injury and stress [15]. In un-
stimulated cells, homodimers or heterodimers of the NF-
κB family members are bound to ankyrin-rich regions of
inhibitor of NF-κB( I κB) proteins. This binding retains the
dimers in the cytoplasm to prevent transcription of target
genes. The NF-κB1/p105 and NF-κB2/p100 precursor pro-
teins, which encode p50 and p52, also behave like IκBs, with
the ankyrin repeats in their carboxyl-terminal. The IκBs and
NF-κB2/p100 are important targets of inducible regulatory
pathways that mobilize active NF-κB to the nucleus. NF-κB
signaling cascade results in the activation of classical/canon-
ical or the alternative/noncanonical pathway depending on
the type of stimuli (Figure 2). In general, growth factors and
inﬂammatory mediators, hormones, and other signals can
activate the classical NF-κBp a t h w a y .
The well known that NF-κB-dependent regulation of
inﬂammatory response by TNF-α along the classical activa-
tion pathway includes recruitment and autoubiquitination
of TRAFs through K63-linked ubiquitin chains. These ubiq-
uitin chains act as molecular bridges that connect TRAF6
with TAB-TAK complex, which further induces IKK phos-
phorylation and activation (Figure 2). The latter phospho-
rylates IκB-α become ubiquitinated and is rapidly degraded
through proteasome. Thus, NF-κB complexes (p65/p50) are
freed and translocate to the nucleus for the expression of
corresponding target genes (Figure 2)[ 16]. The alternative
NF-κB pathway depends on IKKα but not on IKKβ or
NEMO. The target for activated IKKα is the inhibitory
ankyrin protein NF-κB2/p100, which is phosphorylated by
IKKα at its carboxyl terminus. Phosphorylation of NF-κB2/
p100 is followed by the ubiquitin-dependent degradation of
p100 into the p52 product and nuclear translocation of p52
(Figure 2). Examples of stimuli that activate the alternative
pathway include Lymphotoxin (LT)β R, B-cell activating fac-
tor receptor (BAFFR), receptor activator of NF-κB (RANK),
and CD40 [17].
There are several lines of evidence suggesting that dys-
regulation of the NF-κB system may lead to gene expression
patterns involved in tumor growth and invasion. In these
studies, functional blockade of NF-κBw a sa c h i e v e db y
targeting to skin expression a repressor mutant of IκB-α
inhibitory protein (IκBαM). These studies could show spon-
taneous development of malignant SCC in transgenic mice
expressing IκBαM or the production of large neoplasms and
SCC in human skin tissues by coexpression of IκBαMa n d
Ras [18, 19].
One known regulator of nuclear NF-κB activity is BCL3,
a protein closely related to IκB. BCL3 was originally identi-
ﬁed in a subgroup of B cell leukemias that carry a translo-
cation of the immunoglobulin heavy chain (IgH) promoter
adjacent to the BCL3 coding region [20]. Since p50 and p52
lack transactivation domains, BCL3 functions as a tran-
scriptional coactivator through its association with p50 and
p52 (Figure 2). In many diﬀerent tumor types, BCL3 in
association with p50 or p52 promotes oncogenesis through
the activation of cyclin D1. Melanoma, hepatocellular car-
cinoma, and breast cancer are instances where cyclin D1
expression is upregulated due to the BCL3-p50 or BCL3-p52
association [21–23].
3.2. Hedgehog Signaling. The hedgehog (Hh) pathway is one
of the fundamental signal transduction pathways in animal
development, stem-cell maintenance, and carcinogenesis.
The Hh gene was ﬁrst discovered in Drosophila, and mem-
bers of the family have since been found in most metazoans
[24]. Hh proteins are synthesized as precursor proteins and
comprise several diﬀerent motifs and domains consisting of
a signal peptide for protein export, a secreted N-terminal
domainthatactsasasignalingmolecule,andanautocatalytic
C-terminal domain [24].
In general, mature Hh proteins secreted from producer
cells induce eﬀects on target cells expressing Hh receptor
Patched (PTCH) [25]. PTCH indirectly transduces Hh sig-
nals to the intracellular signaling cascade through Smooth-
ened (SMO) which is a typical seven-transmembrane recep-
tor [26]. SMO activation is further mediated through phos-
phorylation of its carboxyl terminal intracellular tail by pro-
tein kinases including protein kinase A (PKA) and casein
kinaseI(CKI).InthepresenceofHhsignaling,SMOinduces
suppressor of fused (SUFU) inactivation and initiates stabi-
lization and nuclear accumulation of GLI (glioma-associated
oncogene) family members (GLI1, GLI2, and GLI3) [27, 28].
Similar to the role of IκB-α in retaining NF-κB in the
cytoplasm in an inactive form, SUFU interacts with GLI in
the cytoplasm to prevent its nuclear translocation and trans-
activation. However, cells treated with an activator of Hh
signaling leads to the ubiquitin-mediated degradation of
SUFU and release of GLI. Unbound GLI in the cytoplasm
actively translocates into the nucleus, where it promotes the
transcription of its target genes that are involved in diﬀerent
cellular processes (Figure 3). The GLI transcription factors
can also inhibit transcription by binding to GLI responsive
genes and by interacting with the transcription complex [29,
30]. In general, GLI1 seems to have only activator functions
whereas GLI2 and GLI3 can be activators or suppressors of
transcription in a context-dependent manner.
Alternative regulation of Hh signaling pathway takes
place directly through ubiquitin-mediated degradation of
GLI, which is facilitated by three diﬀerent ubiquitin ligases:4 Journal of Skin Cancer
Figure 2: The role of CYLD in canonical and noncanonical NF-κB pathway. In the canonical NF-κBp a t h w a y ,N F - κB dimmers such as
p65/p50 are maintained in the cytoplasm by interaction with an IκBα protein. The binding of a ligand to a cell-surface receptor activates
TAK1 which in turn activates an IKK complex, containing-α,- β, and NEMO, which is responsible for phosphorylation of IKK-β. IKK-β
then phosphorylates IκB-α, leading to K48-ubiquitination and degradation of this protein. p65/p50 then freely enters the nucleus to turn on
targetgenes.Thenoncanonicalpathwayislargelyfortheactivationofp100/RelBcomplexesanddiﬀersfromtheclassicalpathwayinthatonly
certain receptor signals, activate this pathway and it proceeds through an IKK complex that contains two IKK-α subunits but not NEMO.
In the noncanonical NF-κB pathway, receptor binding leads to activation of the NF-κB-inducing kinase NIK, which phosphorylates and
activates an IKK-α complex that in turn phosphorylates IκB domain of p100, leading to its partial proteolysis and liberation of the p52/RelB
complex. CYLD blocks canonical NF-κB pathway by the removal of Lys-63 ubiquitinated chains from activated TRAFs, RIP, NEMO, and
BCL3.
SCFβ-Trcp, Cul3-HIB, and Itch [31]. In the absence of Hh,
phosphorylation of GLI by PKA, glycogen synthase kinase 3
(GSK3),andCK1triggersbindingofGLItoSCFβ-Trcpubiq-
uitin ligase complexes and consequent proteolysis. In addi-
tion to SCFβ-Trcp-mediated degradation, GLI proteins are
also subject to proteasome degradation through the action
of Roadkill (Rdx) (also called HIB), which encodes a sub-
strate speciﬁc receptor for the Cul3-based E3 ubiquitin ligase
[32, 33]. Hh signaling induces HIB expression, which serves
as a feedback control limiting GLI activity after pathway
activation. Recently, it has been demonstrated that GLI sig-
naling is suppressed by Numb, an evolutionarily-conserved
developmental protein that has critical roles in cell diﬀer-
entiation. The suppression of GLI signaling involves the
ubiquitin-regulated processing of GLI-mediated by Numb
and the HECT domain E3 ubiquitin ligase Itch [34]. Thus,
diﬀerentE3ubiquitinligaseshaveanimpactontheHhpath-
way at diﬀerent levels to control the spatial and temporal
activity of GLI proteins.
In addition to ubiquitination, several histone-modifying
enzymes and chromatin remodeling proteins have been
shown to inﬂuence the transcriptional activity of GLI pro-
teins. GLI1 and GLI2 are modiﬁed by acetylation and class
I histone deacetylases regulate their transcriptional activities
[35]. Recent study has also identiﬁed Snf5, a core member
of the ATP-dependent switch (SWI)/sucrose nonfermenting
(SNF) chromatin remodeling complex, and several other
SWI/SNF complex subunits as GLI1-speciﬁc interacting pro-
teins. Moreover, inactivation of Snf5, which localizes to GLI1
promoter, resulted in the upregulation of GLI1 expression.
This result indicates that the SWI/SNF complex is a regula-
tor of Hh signaling by suppression of GLI1 transcriptionalJournal of Skin Cancer 5
Figure 3: Downregulation of CYLD in BCC mediated by hedgehog signaling pathway. In the absence of ligand, the hedgehog (Hh) signaling
pathway is inactive (left). Patched (PTCH) inhibits the activity of Smoothened (SMO), which in turn is unable to activate GLI transcription
factors through interactions with FUSED and Suppressor of FUSED (SUFU). The binding of SUFU also prevents the transcription of Hh
target genes. Binding of the Hh ligand inhibits PTCH and activates hedgehog pathway (right) through derepression of SMO and translo-
cation of GlLI to the nucleus. Nuclear GLI activates target gene expression, including PTCH, GLI, and Snail. Expression of Snail leads to
transcriptional inactivation of CYLD by recruitment of Snail to the CYLD promoter.
activity [36]. All three GLI proteins are targets of small ubiq-
uitin-related modiﬁer (SUMO) conjugation. Expression of
the SUMO E3 ligase Pias1 promotes GLI transcriptional
activity, suggesting that GLI protein sumoylation acts as a
potential regulatory mechanism in Hh signaling [37].
The ﬁrst link between the Hh pathway and BCC came
from the discovery of loss-of-function mutations of PTCH1
geneinGorlinsyndrome[25,38].Thesepatientsarestrongly
predisposed to the development of BCCs at early age. It has
been established that the majority of BCCs arise sporadically
on sun exposed areas of the skin and BCCs routinely carry
mutations in PTCH1 [39]. Mutations in several other genes
encoding components of Hh signalling such as SMO, SUFU,
and abnormalities of Hh pathway transcription factors GLI
can also contribute to sporadic BCC development (for paper
see [40]).
4. CYLDand Nonmelanoma SkinCancer
4.1. CYLD and Basal Cell Carcinoma. CYLD is profoundly
downregulated at both the mRNA and protein levels in dif-
ferentstagesofBCCcomparedtokeratinocytesinthenormal
epidermis [41]. Reduced expression of CYLD is a result of
recruitment of the transcription repressor protein Snail to
the CYLD promoter which leads to silencing of its expression
[41]( Figure 3). Snail was identiﬁed as an early GLI1-respon-
sive gene in the skin and has been shown to be coexpressed
with GLI1 in skin tumors [42]. In keratinocytes, the forced
expression of GLI1, or treatment with puromorphamine
(previously found to activate the Hh pathway), elevated the
levels of Snail and inhibited CYLD expression. In contrast,
knockdown of Snail or treatment of mouse BCC cell lines
with cyclopamine, which inhibits the Hh pathway, led to an
increase in the levels of CYLD [41]. The consequences of
the reduced levels of CYLD cause by GLI1-Snail1 signaling
aﬀected proliferation and cell cycle by promoting G1 to S
phase progression. BCL3 was identiﬁed as a CYLD-speciﬁc
substrate in BCC and treatment of BCC cell lines with cyclo-
pamine rescued the expression of CYLD. CYLD in turn re-
duced the ubiquitination and nuclear localization of BCL3
[41]. In addition to BCCs, which arises in mice expressing
GLI1 in the skin, these mice also develop cylindroma and
trichoepitheliomas [43], suggesting that the loss or inactiva-
tion of CYLD in diﬀerent skin cancer diseases can aﬀect the
same signaling pathway.
Molecular genetic analysis has demonstrated the afore-
mentioned mutation at 9q22–31 in 70% of sporadic BCCs
[44, 45]. However, there is no evidence in the literature thus
far that indicates alterations on chromosome 16, where the
CYLD gene is located. LOH on chromosome 16 was also6 Journal of Skin Cancer
Figure 4: Catalytic inactive mutant form of CYLD promotes development of squamous cell carcinoma. Keratinocyte stimulation with
DMBA,TPA,orUV-Bcausesubiquitination-mediatedsignalingandactivationofJNK,NF-κBpathways,andtheupregulationofVEGFgene
expression.Wild-typeCYLD(CYLDWT)byinteractionanddeubiquitinationofitsspeciﬁcsubstrateblocksthepropagationofdownstream
signaling pathways. The mutant form of CYLD (CYLD Mut), which binds to the substrate, is unable to remove K63-polyubiquitin chains
from the target protein and blocks the downstream signaling pathways. In addition, the mutant form of CYLD competes with the wild-type
CYLD for the same binding site on the substrate. Constitutive activation of JNK and NF-κB signaling in CYLD mutant cells (CYLD Mut),
leads to development of squamous cell carcinoma (SCC).
investigated using three microsatellite markers (D16s407,
D16s308, and D16s304) in the BCC originating from skin
a d n e x a lt u m o r s[ 46]. Such tumors are an uncommon but
related group of benign neoplasms that diﬀerentiate towards
epidermal appendages rather than surface epidermis. Laser
capturemicrodissectionshowedLOHinonlyonepatientout
of nine. Moreover, this LOH was identiﬁed in one of the
markers, but not in the others, indicating that CYLD mu-
tation has no role in the development of BCC originating
fromadnexaltumors[46].Furthermore,analysisoftwolarge
nodular BCCs from a 46-year-old man with an almost 20-
year history of multiple discrete and conﬂuent papules and
nodulesonthefaceshowedagermlinesubstitutionmutation
(c.1684 + 1G > A) of the CYLD gene in the DNA isolated
from tissue block and peripheral blood [47]. This previously
uncharacterized mutation occurred in the exon-intron junc-
tion and could aﬀect correct splicing [47]. However, analysis
performed in eight tissue blocks containing malignant BCCs
from the same patient identiﬁed CYLD gene LOH and
sequence mutation without ﬁnding any correlation between
thetumortypeandsomaticevent[47].MutationsinPTCH1,
which activates Hh signaling, were originally identiﬁed in
BCC patients [25, 48]. These mutations are thought to be
the major cause of Hh pathway activation in BCCs. A recent
study by Kazakov et al., analyzing peripheral blood and tu-
mor tissues of a family having small nodular BCC arising
from multiple trichoepitheliomas, found no mutations or
L O Hi nC Y L Do ri nP T C H[ 49].
The Trk family of neurotrophin receptors plays a critical
role in the development and maintenance of the central andJournal of Skin Cancer 7
peripheralnervoussystems.Thishomologousfamilyoftyro-
sine kinase receptors consists of TrkA, TrkB, and TrkC. The
primary ligand for these receptors is nerve growth factor
(NGF) [50]. NGF stimulation of PC12 cells that are derived
from transplantable rat pheochromocytoma promotes K63-
mediated deubiquitination of TrkA by CYLD which further
aﬀects TrkA internalization and signaling [51, 52]. Aside
from CYLD interfering with TrkA signaling, TrkB and TrkC
are overexpressed in tumors lacking CYLD expression in-
cluding cylindroma, spiradenoma, trichoepithelioma, and
BCC [53] .T h ei n c r e a s e dl e v e lo fT r k Ci nB C Ch a sb e e ni m -
plicated in the proliferative advantage of cells, where con-
stitutively active Hh signaling due to the loss of functional
PTCH occurs. As it was shown that CYLD can interfere with
Trksignaling[53],althoughitisnotentirelyclearhowlossof
CYLD can promote overexpression of TrkC, a block of TRK
receptor signaling has been proposed to represent a novel
therapeutic target in tumors with loss of CYLD function
including BCC [53].
4.2. CYLD and Squomous Cell Carcinoma. In a large tissue
microarray-based study consisting of 131 patients with SCC
tumor specimens, the expression levels of CYLD were not
altered [54]. Furthermore, skin tumors chemically induced
by using DMBA/TPA in CYLD-deﬁcient mice resulted in the
development of skin papillomas without any signs of SCC
[55]. Instead, two recent studies using transgenic animals
were able to identify the role of CYLD mutation in the devel-
opment of SCC [56, 57]. Genetically modiﬁed complete
knockoutversusknock-inmousemodelscouldbetheexpla-
nation for the diﬀerences in the phenotype.
TPA or UV-B stimulation of CYLD-deﬁcient keratino-
cytes causes K63 ubiquitination-mediated nuclear transloca-
tion of BCL3. In the nucleus, BCL3 together with p52 binds
to the cyclin D1 promoter and increases proliferation of
these cells. In contrast, wild-type keratinocytes have reduced
proliferation rates compared to the knockout cells due to the
interaction of BCL3 with CYLD in the cytoplasm, where
removal of K63 ubiquitin chains by CYLD occurs [55].
Transgenic animals expressing the mutant form of CYLD
(CYLDC/S) which are unable to act as DUBs convert epider-
mal cells into malignant cells. The tumor epidermal cells ex-
pressing CYLDC/S in addition to being unable to remove
ubiquitin chains from IKK (a downstream eﬀector in NF-κB
signaling)alsocontainanactiveformofp65.Moreover,these
cells show an increase in the number of cells having nuclear
localized BCL3 and p52 responsible for cyclin D1 expression
[57]. In addition, epithelial cells from CYLDC/S mice favor
the malignancy by enhancing cell proliferation, migration,
survival, and angiogenesis. This phenotype is partially de-
pendent on elevated levels of vascular endothelial growth
factor(VEGF)(Figure 4).However,futurestudiesareneeded
to establish downstream signaling for CYLDC/S-mediated
changes in VEGF levels. It is known that VEGF overexpres-
sion in murine epidermis predisposes mice to tumor devel-
opment [58] and very recently it has been reported that
VEGF plays a signiﬁcant role not only in the ﬁrst stage of
angiogenesis establishment, but also in the advanced stages
of several malignant tumor progressions including nonmel-
anoma skin cancer [58].
In another relevant study, mice expressing keratin 14
promoter-driven CYLD catalytic inactive mutant (CYLDm,
lacking the 21 amino acid residues at the C-terminal end)
did not develop any spontaneous skin tumors [56]. Instead,
exposure of newborn CYLDm mice to DMBA/TPA resulted
in cell malignancy and metastasis in a JNK/AP1-dependent
manner [56]. In this pathway, CYLDm increased the basal
levels of c-Jun and c-Fos and sustained their activation status
in response to EGF treatment in an ubiquitin- and protea-
some-dependent manner [56]. The increased nondegradable
c-Jun/c-Fos protein was suggested as being responsible for
malignant and metastatic tumor development in cancers
associated with loss of functionmutations in the CYLD gene
(Figure 4)[ 56].
5. Summary
We have surveyed the role of the deubiquitination enzyme
CYLD in nonmelanoma skin cancers (BCCs and SCCs).
BCCs diﬀer from SCCs in many respects. While BCCs devel-
op de novo, formation of skin SCC is a multiple-step proc-
ess. BCCs exhibit a relatively simple genotype with few aber-
rations and show themselves to be highly independent of the
immune system. Further, PTCH and SMO gene mutations
areimportantinthedevelopmentofBCCs[59].Ontheother
hand, SCCs develop from precursor lesions and accumulate
a highly complex genotype. The great number of chromo-
somal aberrations, for example, loss of 3p, loss of 9p, and
gain of 3q, 9q, and 11q as well as gene mutations such as
p53, p16INK4,R a s ,c - m y c ,a n dE G F R ,h a sb e e nr e l a t e dt oS C C
development [60, 61].
In BCC, suppression of the CYLD gene product is caused
by the transcriptional regulator Snail, whose expression is
activated by GLI1. Since Downregulation or even loss of
CYLD expression could be observed in the early phase of
BCC samples with diﬀerent degrees of invasive behavior and
tumor size, this suggests that CYLD repression occurs in an
early stage of BCC development. BCC is the most common
form of cancer in humans and is believed to arise from hair
follicles. Since Snail and GLI1 transcripts are elevated in nor-
mal anagen (growth) phase of hair follicles, in contrast to
CYLD whose expression is elevated only during the catagen
(regression) phase of the hair cycle, one might hypothesize
that disruption of expression of these genes may initiate
growth of BCC. Downregulation of CYLD in BCC was also
showntointerferewithTrkCexpressionandsignaling,which
under normal conditions is expressed in hair follicles. It is
highly probable that elevated TrkC expression promotes the
proliferative advantage of cells in cases where constitutively
activeHhsignalingfollowinglossoffunctionalPTCHoccurs.
As the level of CYLD is unchanged in SCC compared to
epidermal keratinocytes, catalytic inactivation of CYLD in
skin has been connected to the conversion of epidermal cells
to malignant cells. SCC derived from CYLD mutant cells
showsanincreaseinthenuclearlocalizationofBCL3andp52
as well as an increase in cyclin D1 expression. In addition,
VEGF expression, which is a well-known growth factor that8 Journal of Skin Cancer
stimulates angiogenesis and metastasis, was also elevated.
The role of VEGF in the advanced stages of tumor progres-
sion in nonmelanoma skin cancer has recently been identi-
ﬁed [58].
In general, ubiquitination-dependent degradation plays
a major role in the progression of skin cancers. Recently,
the proteasome inhibitor Bortezomib (Velcade or PS-341),
the ﬁrst therapeutic proteasome inhibitor for treating re-
lapsed multiple myeloma, was shown to suppress the growth
of SCC cell lines by inhibiting the NF-κB pathway and VEGF
levels [62]. Furthermore, cisplatin or cetuximab also en-
hanced the eﬀect of bortezomib in SCC cell lines [63, 64].
It is not clear thus far whether Bortezomib has any eﬀect on
BCCs, but the inhibition of Hh signaling is frequently em-
ployed as a useful treatment for this type of cancer. Cyclo-
pamine, GDC-0449, and LDE-225 are a few examples of
compounds that are selective Hh inhibitors and are currently
under investigation in ongoing trials.
Previous studies have identiﬁed correlations in the alter-
ation of Hh and Wnt pathways in BCCs [65–69] and recently
a population of cancer stem cells in mouse early SCCs dem-
onstrating dependence on β-catenin (Wnt/β-catenin sig-
naling) activation. In human cylindroma, CYLD negatively
regulates Wnt/β-catenin signaling via deubiquitination of
Dishevelled, which is a key component in Wnt-mediated β-
catenin nuclear translocation. Further studies need to estab-
lish whether CYLD regulation of Wnt signaling has a direct
eﬀect on the development of BCCs and SCCs.
6. Conclusions andFutureDirections
The human genome encodes a large number of ubiquitin
ligasesandDUBsinvolvedintheregulationofdiﬀerentpath-
ways. The challenge in this ﬁeld is to ﬁnd the signaling path-
ways for ubiquitin ligases and DUBs that are speciﬁcally
linked to cancer etiology. CYLD mutations or lack of CYLD
expression has been connected with the development or
progression of diﬀerent types of skin cancer. In order to
arrive at novel molecular strategies for diﬀerent skin cancer
prevention,futureworkneedstofocusonthesignalingpath-
wayin deﬁned targetcellpopulations. Thisis alsoimportant,
since BCC, which very rarely metastasizes, is believed to arise
from hair follicles, whereas SCC, which has a greater me-
tastatic potential, arises from the interfollicular epidermis.
M oreov er ,lossofCYLDexpressionleadstoBCCwhilemuta-
tion/s leading to catalytic inactivation of CYLD produces
SCC. Such diﬀerences may explain why the function and
substrate of CYLD diﬀer depending on the cell of origin and
tumor type.
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